Study of brain GABA signals in Dravet syndrome
Part of Brain & nervous system clinical trials.
This study looks at “GABA signals” in the body/brain to learn more about Dravet syndrome and how it may relate to seizures. If you have Dravet syndrome caused by a specific SCN1A gene change, you may be asked to provide genetic test results and help with study visits so researchers can compare biomarker readings.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (a parent/caregiver) must be able to read, understand, and sign consent; if the child can, they must agree (assent).
- The child must be between 0 and 18 years old at the time you sign consent.
- The child must have a confirmed SCN1A genetic test result that is labeled “pathogenic” or “likely pathogenic.”
- Before the first seizure, development should have been normal (no clear developmental problems yet).
- The first seizure should have started between 3 and 5 months of age and match specific seizure types.
- A pediatric neurologist must have diagnosed the child with Dravet syndrome.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows children with Dravet syndrome caused by a specific SCN1A gene change to understand how the condition develops over time. It may help families know more about what to expect.
This study tests a new gene therapy called ION337 designed to treat Dravet syndrome, a severe childhood epilepsy caused by a SCN1A gene mutation. The therapy is given as a spinal fluid injection and aims to reduce seizures in children ages 2–12.
This study uses a special PET-MRI scan to look at a brain chemical pathway linked to serotonin (a mood-regulating substance) in people with Dravet syndrome or certain types of epilepsy, and in healthy volunteers. It may help understand how the brain works in these conditions.
This early-phase study tests how safe ETX101 is and whether it can help reduce seizures in young children with Dravet syndrome caused by an SCN1A gene change. It mainly enrolls infants and children with a specific type of seizure history and genetic result.
This Phase 3 study tests EPX-100 (clemizole) to help reduce seizures in people with Dravet syndrome whose seizures are not fully controlled by current anti-seizure medicines. You may consider this study if your Dravet diagnosis is confirmed and your medical situation fits the specific rules about medicines and seizure causes.
This study tests an experimental drug called zorevunersen for people with Dravet syndrome. It aims to see if the drug can reduce seizures and improve safety.
Hear when a new Dravet Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.